| Dr John Arraf, MD | |
|
700 E Marshall Ave, Longview, TX 75601-5580 | |
| (403) 818-4374 | |
| Not Available |
| Full Name | Dr John Arraf |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 33 Years |
| Location | 700 E Marshall Ave, Longview, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1972276897 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | MED-PHYS-LIC-100198 (Montana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Tucson Medical Center | Tucson, AZ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Ias Arizona Pllc | 7517312648 | 145 |
News Archive
A host of special molecules called nuclear RNA-binding proteins (RBPs), when misplaced outside the nucleus, form the harmful clumps seen in several brain disorders, including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS).
Estrogen seems to act like a middleman in its positive effect on the brain, raising the possibility that future drugs may bypass the carcinogenic hormone altogether while reaping its benefits.
Synta Pharmaceuticals Corp. today announced results from an interim analysis of the Phase 2b portion of the GALAXY trial, a global, randomized, multi-center Phase 2b/3 study designed to evaluate the efficacy and safety of the Company's lead Hsp90 inhibitor, ganetespib, as second-line treatment for advanced non-small cell lung cancer (NSCLC).
A genetic map of an aggressive childhood brain tumor called medulloblastoma has helped researchers identify a new generation anti-cancer drug that can be repurposed as an effective treatment for the disease.
› Verified 8 days ago
| Entity Name | Ias Arizona Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1689359747 PECOS PAC ID: 7517312648 Enrollment ID: O20231010003129 |
News Archive
A host of special molecules called nuclear RNA-binding proteins (RBPs), when misplaced outside the nucleus, form the harmful clumps seen in several brain disorders, including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS).
Estrogen seems to act like a middleman in its positive effect on the brain, raising the possibility that future drugs may bypass the carcinogenic hormone altogether while reaping its benefits.
Synta Pharmaceuticals Corp. today announced results from an interim analysis of the Phase 2b portion of the GALAXY trial, a global, randomized, multi-center Phase 2b/3 study designed to evaluate the efficacy and safety of the Company's lead Hsp90 inhibitor, ganetespib, as second-line treatment for advanced non-small cell lung cancer (NSCLC).
A genetic map of an aggressive childhood brain tumor called medulloblastoma has helped researchers identify a new generation anti-cancer drug that can be repurposed as an effective treatment for the disease.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr John Arraf, MD 350 N Meridian Rd # 7426, Kalispell, MT 59901-9998 Ph: (403) 818-4374 | Dr John Arraf, MD 700 E Marshall Ave, Longview, TX 75601-5580 Ph: (403) 818-4374 |
News Archive
A host of special molecules called nuclear RNA-binding proteins (RBPs), when misplaced outside the nucleus, form the harmful clumps seen in several brain disorders, including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS).
Estrogen seems to act like a middleman in its positive effect on the brain, raising the possibility that future drugs may bypass the carcinogenic hormone altogether while reaping its benefits.
Synta Pharmaceuticals Corp. today announced results from an interim analysis of the Phase 2b portion of the GALAXY trial, a global, randomized, multi-center Phase 2b/3 study designed to evaluate the efficacy and safety of the Company's lead Hsp90 inhibitor, ganetespib, as second-line treatment for advanced non-small cell lung cancer (NSCLC).
A genetic map of an aggressive childhood brain tumor called medulloblastoma has helped researchers identify a new generation anti-cancer drug that can be repurposed as an effective treatment for the disease.
› Verified 8 days ago
Sayojirao Venkata Kodali, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 906 Judson Rd, Longview, TX 75601 Phone: 903-655-1313 Fax: 903-657-6067 | |
Roger Seth Baker, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 2901 N. 4th St, Longview, TX 75605 Phone: 903-247-2050 Fax: 903-934-8280 | |
Stanley Tunstall, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 2901 N. 4th St, Longview, TX 75605 Phone: 903-247-2050 Fax: 903-934-8280 | |
Allen Ross Morton, M.D. Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 703 E Marshall Ave, #4002, Longview, TX 75601 Phone: 903-247-2050 Fax: 903-247-2054 | |
Mark Johnston Williams, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 2901 N. 4th St., Longview, TX 75605 Phone: 903-247-2050 Fax: 903-934-8280 | |
Mr. Michael Christopher Roberts, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 906 Judson Rd, Longview, TX 75601 Phone: 903-655-1313 Fax: 903-657-6067 | |
Lamont Steven Berg, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 703 E Marshall Ave, #4002, Longview, TX 75601 Phone: 903-247-2050 Fax: 903-247-2054 |